The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | HERIZON-GEA-01: HRQoL with first-line zanidatamab-based regimens in HER2+ mGEA
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, explores health-related quality of life (HRQoL) outcomes from the Phase III HERIZON-GEA-01 trial (NCT05152147), comparing zanidatamab plus chemotherapy with or without tislelizumab against trastuzumab plus chemotherapy as first-line treatment for HER2-positive advanced gastroesophageal adenocarcinoma (mGEA). Physical functioning and global health status scores remained broadly similar across arms, with only small, clinically insignificant differences favoring the control arm. These findings suggest zanidatamab-containing regimens preserve quality of life while providing meaningful survival benefits, supporting their use in this first-line setting. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
